What is the recommended dosage regimen for the Trimbow (beclomethasone dipropionate/formoterol/glycopyrronium) inhaler?

Trimbow Dosage Recommendation

The recommended dosage of Trimbow (beclomethasone dipropionate/formoterol fumarate/glycopyrronium) is two inhalations twice daily (morning and evening), with the strength selected based on disease severity: 87/5/9 mcg for moderate asthma or COPD, or 172/5/9 mcg for severe uncontrolled asthma.

Dosing by Indication and Severity

For Asthma (Uncontrolled on ICS/LABA)

• Medium-strength (87/5/9 mcg): Two inhalations twice daily for patients with moderate asthma previously on medium-dose ICS/LABA combinations 1

• High-strength (172/5/9 mcg): Two inhalations twice daily for patients with severe uncontrolled asthma previously on high-dose ICS/LABA or free ICS/LABA/LAMA combinations 1, 2

The high-strength formulation demonstrated superior reduction in severe exacerbations compared to other single-inhaler triple therapies, with significant improvements in lung function (FEV1 increase of 142 mL at 12 months) and asthma control (ACT score improvement of 3.9-4.8 points, exceeding the minimal clinically important difference) 1, 3.

For COPD

• Standard dose (87/5/9 mcg): Two inhalations twice daily for patients with moderate to very severe COPD (GOLD Grade 2-4) with persistent symptoms and exacerbation history 4, 5

This dosing achieved a 57.4% reduction in moderate exacerbations and 27.3% reduction in severe exacerbations over 52 weeks in real-world settings 4.

Administration Details

Critical administration points:

• Administer via pressurized metered-dose inhaler (pMDI)
• Take at consistent times: morning and evening, approximately 12 hours apart
• The extrafine formulation allows enhanced small airway deposition of all three components
• Do not exceed the prescribed dose; excessive use may cause cardiovascular effects 6

Treatment Pathway Considerations

When initiating Trimbow:

• Most patients (75.7%) transitioning to medium-strength come from fixed ICS/LABA combinations 1
• Patients starting high-strength typically come from either fixed ICS/LABA (52.9%) or free ICS/LABA/LAMA combinations (43.2%) 1
• Discontinue regular use of short-acting beta-agonists; reserve for acute symptom relief only 7, 6
• Do not combine with other inhaled medications containing long-acting beta-agonists 6

Expected Outcomes and Monitoring

Timeline for clinical benefit:

• Bronchodilation onset: median 11.7-13.1 minutes after first dose 6
• Peak effect: 2 hours post-dose 6
• Sustained improvements in lung function, symptoms, and exacerbation rates evident by 12 weeks 1, 4
• Clinical remission rates: 45.6% in first year, increasing to 59.3% in subsequent years 1

Key monitoring parameters:

• Rescue medication use should decline (from ~6 puffs/week to ~3.6 puffs/week by month 12) 1
• Systemic corticosteroid use should decrease (from 33.2% to 12.4% of patients by month 12) 1
• If symptoms worsen, treatment becomes less effective, or rescue medication use increases, seek immediate medical attention rather than increasing Trimbow dose 6

Important Safety Considerations

Common pitfalls to avoid:

• Never use as monotherapy for asthma without the ICS component—this increases risk of asthma-related death 8, 6
• Not indicated for acute symptom relief; do not use extra doses for acute exacerbations 6
• Maximum daily dose is four inhalations total (two inhalations twice daily); exceeding this may cause significant cardiovascular effects 6
• Patients should not stop therapy abruptly without medical guidance, even if symptoms improve 6

Patient counseling essentials:

• Potential adverse effects include palpitations, tremor, headache, dry mouth, and hypokalemia 6
• Proper inhaler technique is critical for effectiveness 9
• Continue therapy consistently; 87.1% of patients in real-world studies remained on treatment throughout follow-up 1